ArticleEuropean journal of nuclear medicine and molecular imaging2013
Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.
Article in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.European journal of nuclear medicine and molecular imaging · 2015Pooled it
- Trial
- Trial
- Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.European journal of nuclear medicine and molecular imaging · 2017Trial
- Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.Nuclear medicine communications · 2016Trial
- Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Trial
- Toward reproducible metabolic tumor volume quantification in endometrial cancer: optimizing [¹⁸F]FDG PET/CT tumor segmentation methods.EJNMMI research · 2026Article
- Article
- Predictive significance ofFrontiers in oncology · 2025Article
- Clinico-pathological factors and [BMC medical imaging · 2024Article
- Analysis of Molecular Imaging Biomarkers Derived from [Cancers · 2024Article
- Prostate-Specific Membrane Antigen-Positron Emission Tomography-Guided Radiomics and Machine Learning in Prostate Carcinoma.Cancers · 2024Review
- Review on radiomic analysis inCancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Principal Component Analysis Applied to Radiomics Data: Added Value for Separating Benign from Malignant Solitary Pulmonary Nodules.Journal of clinical medicine · 2023Article
- Differences in Tumour Aggressiveness Based on Molecular Subtype and Race Measured by [Diagnostics (Basel, Switzerland) · 2023Article
- Prognostic value of baselineRadiation oncology (London, England) · 2023Article
- Prognostic value of [18F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors.Frontiers in oncology · 2023Article
- Principal component analysis of texture features derived from FDG PET images of melanoma lesions.EJNMMI physics · 2022Article
- Volumetric parameters from [Journal of neuroendocrinology · 2022Observational
- Prognostic value of total metabolic tumour volume and therapy-response assessment by [European radiology · 2022Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data available in patients suffering from squamous cell carcinoma of the head and neck, lung carcinoma, oesophageal carcinoma and gynaecological malignancies suggest that metabolic tumour volume and to a lesser extent total lesion glycolysis have the potential to become valuable in the imaging of human solid tumours as prognostic biomarkers for short- to intermediate-term survival outcomes, adding value to clinical staging, for assessment of response to treatment with neoadjuvant and concurrent chemotherapy, and for treatment optimization; for example, based on early treatment response assessment using changes in metabolic tumour volume over time, it might be possible to select patients who require a more aggressive treatment to improve their outcome. Prospective studies enrolling consecutive patients, adopting standardized protocols for FDG PET acquisition and processing, adjusting for potential confounders in the analysis (tumour size and origin) and determining the optimal methodology for determination of these novel markers are mandatory.
Indexed as
Identifiers
23151913What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.